Savolitinib Shows Potential for Patients with NSCLC and MET Exon 14 Skipping Mutations

2020 Year in Review: Non–Small-Cell Lung Cancer —February 6, 2021


Lung Cancer

Savolitinib had promising antitumor activity in patients with METex14+ NSCLC and showed acceptable tolerability.

Patients with non–small-cell lung cancer (NSCLC) and MET exon 14 skipping mutations (METex14+) have unmet medical needs. Pulmonary sarcomatoid carcinoma (PSC), a rare type of NSCLC, has a poor prognosis and a high incidence of METex14+. The oral MET tyrosine kinase inhibitor savolitinib has been shown to have antitumor activity in combination with osimertinib in patients with NSCLC and EGFR and MET-amplified mutations.

This multicenter, multicohort, single-arm phase 2 study evaluated savolitinib treatment in patients with unresectable or metastatic METex14+ PSC and other NSCLC for safety, efficacy, and pharmacokinetics. A central laboratory confirmed MET mutations. A once-daily dose of savolitinib (600 mg for weight ≥50 kg or 400 mg for weight <50 kg) was administered until disease progression or intolerable toxicity. Evaluation of the tumor was performed every 6 weeks in the first year, and subsequently every 12 weeks. An independent review committee (IRC) evaluated the objective response rate (ORR) as a primary end point. This study reports the results of a cohort of patients who had no previous MET treatments.

From a pool of 593 patients, 87 were identified with the METex14+ mutation, of which 70 were treated with savolitinib. The demographics of the cohort included a median age of 68.7 years (range, 51.7-85.0 years), 58.6% male, 92.9% had stage IV cancer, 60% had previous treatments, 57.1% had adenocarcinoma, 35.7% had PSC, and 7.2% had other pathologic types.

The IRC evaluated 61 patients based on those who had ≥1 lesions at baseline and had ≥1 postbaseline evaluations or postbaseline radiologic disease progression. The evaluated cohort had an ORR of 47.5% (95% confidence interval [CI], 34.6%-60.7%) and a disease control rate of 93.4% (95% CI, 84.1%-98.2%); the median duration of response had not been reached. The median progression-free survival among all savolitinib-treated patients was 6.8 months (95% CI, 4.2-13.8). Peripheral edema, nausea, increased aspartate aminotransferase/alanine aminotransferase, vomiting, and hypoalbuminemia were the most common treatment-related adverse events (TRAEs). The incidence of grade ≥3 TRAEs was 41.4%, and the incidence of TRAEs leading to discontinuation of treatment was 14.3%. The most common TRAEs leading to discontinuation of treatment were liver injury and hypersensitivity (both at 2.9% incidence).

Lu S, et al. J Clin Oncol. 2020;38(suppl 15):Abstract 9519.

Related Articles
Importance of Early Detection in Lung Cancer: Elevating the Navigator’s Role
July 2022 Vol 13, No 7
With a malignancy like lung cancer, early detection can quite literally mean the difference between life and death. Despite this, lung cancer screening and incidental pulmonary nodule (IPN) management are still sorely lacking in the United States, according to Kim Parham, BSN, RN, CB-BN, vice president, Strategic Partnerships and Clinical Liaison, Thynk Health, and Shawn Perkins, BSN, RN, OCN, a thoracic services nurse navigator at Cone Health Cancer Center at Alamance Regional.
2022 Midyear Review: Non–Small-Cell Lung Cancer
Special Issues and Supplements
Anxiety and Depression in Advanced Lung Cancer Patients Affected by Symptoms and Therapy
Web Exclusives
Anxiety and depression in patients with advanced lung cancer are associated with poor outcomes when untreated. Radiotherapy, breathlessness, and fatigue are among top predictors of these debilitating conditions.
Last modified: February 8, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State

    Please enter your mailing address.

    Address Line 2
    Zip Code